Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 7, 2012 - Issue
Submit an article Journal homepage
105
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Characterization of outcomes 1 year after endoscopic thermal vapor ablation for patients with heterogeneous emphysema

Felix JF Herth1 Pneumology and Critical Care Medicine, Thoraxklinik Heidelberg, Heidelberg, GermanyCorrespondence[email protected]
,
Armin Ernst2 St Elizabeth’s Medical Center, Boston, MA, USA
,
Kimberly M Baker3 University of Iowa, Iowa City, IA, USA
,
Jim J Egan4 Advanced Lung Disease Program, Mater Misericordiae University Hospital, Dublin, Ireland
,
Mark H Gotfried5 Pulmonary Associates, Phoenix, AZ, USA
,
Peter Hopkins6 Lung Transplant Unit, Prince Charles Hospital, Chermside, Australia
,
Franz Stanzel7 Zentrum für Pneumologie, Hemer, Germany
,
Arschang Valipour8 Ludwig-Boltzmann-Institute for COPD, Otto-Wagner-Hospital, Vienna, Austria
,
Manfred Wagner9 Klinikum Nürnberg, Nürnberg, Germany
,
Christian Witt10 Pneumology, Charité Campus-Mitte, Berlin, Germany
,
Steven Kesten11 Uptake Medical Corp, Tustin, CA, USA
&
Gregory Snell12 Allergy Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne, Australia
 show all
Pages 397-405 | Published online: 18 Jul 2012

Figures & data

Table 1 Baseline characteristics of 44 patients treated with InterVapor

Figure 1 Change from baseline in treated upper lobe and ipsilateral lower lobe volumes 6 and 12 months after InterVapor treatment.

Note: *P < 0.05 vs baseline.
Abbreviations: UL, upper lobe; LL, lower lobe; mo, months.
Figure 1 Change from baseline in treated upper lobe and ipsilateral lower lobe volumes 6 and 12 months after InterVapor treatment.

Table 2 Change from baseline at 6 and 12 months in pulmonary function (absolute change and change in percent of predicted normal) following InterVapor

Figure 2 Change from baseline in FEV1 (mL and % predicted) 6 and 12 months after InterVapor treatment.

Notes: *P < 0.05 vs baseline; †P < 0.05 12 months vs 6 months.

Abbreviation: FEV1, forced expiratory volume in 1 second.

Figure 2 Change from baseline in FEV1 (mL and % predicted) 6 and 12 months after InterVapor treatment.Notes: *P < 0.05 vs baseline; †P < 0.05 12 months vs 6 months.Abbreviation: FEV1, forced expiratory volume in 1 second.

Figure 3 Change from baseline in RV (mL and % predicted) 6 and 12 months after InterVapor treatment.

Note: *P < 0.05 vs baseline.
Abbreviation: RV, residual volume.
Figure 3 Change from baseline in RV (mL and % predicted) 6 and 12 months after InterVapor treatment.

Table 3 SGRQ total score and domains at baseline and change from baseline at 6 and 12 months following InterVapor

Table 4 Changes in efficacy outcomes at 6 and 12 months according to GOLD stage III and GOLD stage IV disease severity

Table 5 Changes in efficacy outcomes at 6 and 12 months according to HI > 1.6 and HI < 1.6

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.